Suppr超能文献

对患有尿路感染的儿童进行了血清和尿液中头孢泊肟水平测定以及尿液中的时间杀菌曲线测定。

Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections.

作者信息

Casellas J M, Tome G, Exeni R, Grimoldi I, Goldberg M, Farinati A E

机构信息

Infectious Diseases Dept. Universidad Católica, Buenos Aires, Argentina.

出版信息

Pathol Biol (Paris). 1993 Apr;41(4):385-91.

PMID:8233640
Abstract

Since resistance to several oral antimicrobials useful for the treatment of pediatric urinary tract infections (UTI) is overwhelming in Argentina, an in vitro investigation was performed testing 400 isolates obtained from urines of children suffering UTI's, 200 collected in 1990 and 200 in 1991. Their susceptibility against oral antimicrobials marketed in Argentina and appropriate for the treatment of UTI was determined by the agar dilution methods. An increase of the resistance to aminopenicillin combined with beta-lactamase inhibitors and to fluoroquinolones was observed comparing the two periods. Cefpodoxime (CPD), cefixime and fluoroquinolones except norfloxacin were the sole oral antimicrobials showing in vitro activity at the 90 per cent level. Unfortunately fluoroquinolones are not yet approved for pediatric use. Consequently we realized an in vitro and in vivo pharmacokinetic study in order to determine CPD activity against E. coli isolated in UTI cases. Five children (6-10 y) showing E. coli UTI infections received 10 mg/kg/d CPD in a single oral daily dose and were treated up to 10 days, 3 had lower UTI and 2 upper UTI. All patients were clinical and bacteriologically cured. Cultures obtained up to 4 weeks after treatment were negative. CPD serum levels at 2 hours after the first dose of treatment showed a median of 2.7 mg/l (2.3-3.4 range). Bactericidal serum titers at the same time against the patients own strain and an E. coli TEM-1 hyperproducer strain (MIC 4,096 mg/l for ampicillin and 0.5 mg/l for CPD) showed a median value of 1/8 against patients strains and 1/2 against the THP strain.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

由于在阿根廷,对几种可用于治疗儿童尿路感染(UTI)的口服抗菌药物的耐药性问题极为严重,因此进行了一项体外研究,检测了从患UTI儿童尿液中分离出的400株菌株,其中200株于1990年收集,200株于1991年收集。通过琼脂稀释法测定了它们对在阿根廷销售的、适用于治疗UTI的口服抗菌药物的敏感性。与两个时期相比,观察到对氨基青霉素联合β-内酰胺酶抑制剂和氟喹诺酮类药物的耐药性有所增加。头孢泊肟(CPD)、头孢克肟和除诺氟沙星外的氟喹诺酮类药物是仅有的在90%水平显示体外活性的口服抗菌药物。不幸的是,氟喹诺酮类药物尚未被批准用于儿科。因此,我们进行了一项体外和体内药代动力学研究,以确定CPD对UTI病例中分离出的大肠杆菌的活性。5名患有大肠杆菌UTI感染的儿童(6 - 10岁)接受每日单次口服10 mg/kg/d的CPD,治疗长达10天,其中3例为下尿路感染,2例为上尿路感染。所有患者临床和细菌学治愈。治疗后长达4周获得的培养物均为阴性。首次给药后2小时的CPD血清水平中位数为2.7 mg/l(范围2.3 - 3.4)。同一时间针对患者自身菌株和一株大肠杆菌TEM - 1高产菌株(氨苄西林的MIC为4,096 mg/l,CPD的MIC为0.5 mg/l)的杀菌血清效价,针对患者菌株的中位数为1/8,针对THP菌株的中位数为1/2。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验